explore -WSS

explore

author：focus 2025-09-30 23:33:03 - browse：119

David Sabatini at home — David Sabatini posed at his home in Cambridge in 2022. Craig F. Walker/Boston Globe

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his lofty positions after being accused of violating sexual harassment policies in 2021, is rejoining the Boston scientific community as head of a research group at a new laboratory under the umbrella of a Czech-based scientific institute.

Sabatini, who has denied harassing anyone and filed litigation over the claims, has been working since last October in a senior research position at the Institute of Organic Chemistry and Biochemistry, in the Czech Republic capital of Prague, investigating scientific questions in the areas of cell growth and metabolism, similar to his past research at Whitehead.

The Czech institute, known as IOCB Prague, is realizing a long-held ambition to expand into the Boston biotech hub, confirmed the institute’s director, Jan Konvalinka.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： White House touts steps to stem shortages of cancer treatments

focus

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

FDA panel endorses Alnylam’s heart drug — after picking it apart

PEPFAR is under serious threat — and so is global health

UCB departs biotech trade group BIO

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

New Covid vaccine is recommended for everyone 6 months or older

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

Activists slam private health insurers over coverage restrictions

3 medical device trends to watch in 2024

Apple is now the first public company to be valued at $3 trillion

Generate Biomedicines machine learning biotech raises $273M

Sports medicine is finally prioritizing gender equality

Generate Biomedicines machine learning biotech raises $273M

Supreme Court strikes down use of affirmative action

White House touts steps to stem shortages of cancer treatments

State Dept. review finds Biden bears some blame for Afghanistan failures

PEPFAR is under serious threat — and so is global health

hotspot

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Acelyrin, a rare IPO success, stumbles in its first big test

Burning questions for the 2024 JPM Healthcare Conference

Ahead of JPM, here's who's profiting most in health care

New weight loss drugs work. But how can they best be used?

Burning questions for the 2024 JPM Healthcare Conference

focus

entertainment

focus

focus